← Eichor
Condition: Minimal Residual Disease Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Minimal Residual Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06511882Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06426511MRD Response-adapted Allo-HSCT for Adverse-risk AML
NA · 1 location(s) · Peking University People's Hospital · NCT06301425Risk Stratification and MRD-driven Maintenance for MM After ASCT
NA · 4 location(s) · Peking University People's Hospital · NCT06697483Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Phase 1 · 1 location(s) · University of Illinois at Chicago · NCT05192122Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07500441Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Ind
Phase N/A · 1 location(s) · Massachusetts Eye and Ear Infirmary · NCT06744296CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
Phase 2 · 1 location(s) · UNICANCER · NCT06450314Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT05196087Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
Phase N/A · 1 location(s) · JaxBio Ltd · NCT06963307Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Phase 2 · 1 location(s) · Sheng-Li Xue, MD · NCT05940961Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06718244Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Phase N/A · 7 location(s) · Zhujiang Hospital · NCT06157060Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cance
NA · 13 location(s) · City of Hope Medical Center · NCT07125729ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
NA · 1 location(s) · Hua-Jay J Cherng, MD · NCT06693830Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Phase N/A · 6 location(s) · University Medical Center Groningen · NCT06111807A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLB
Phase 2 · 1 location(s) · Danielle Wallace · NCT06828991Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Phase 2 · 1 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06253650Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
Phase 3 · 3 location(s) · Seoul National University Hospital · NCT05534087Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Phase 1 · 1 location(s) · University of California, Irvine · NCT04920032Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Dis
NA · 2 location(s) · M.D. Anderson Cancer Center · NCT05676450Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05091372To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07291921Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple My
Phase 2 · 2 location(s) · University of Illinois at Chicago · NCT05344833Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Phase N/A · 1 location(s) · Instituto do Cancer do Estado de São Paulo · NCT05959720Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06144606Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Phase 1 · 1 location(s) · Changhai Hospital · NCT05240950
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.